A Phase 1 interventional study of 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 in Tuberculosis, Tuberculosis, Pulmonary and Bacterial Infections Respiratory, sponsored by Michael Hoelscher. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-31.
Sponsored by Michael Hoelscher · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a Phase 1, single-center, open-label study to investigate the absorption, metabolism, and excretion of BTZ-043 after a single oral administration of 500 mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 in 4 healthy adult male subjects
A total of 4 evaluable subjects completing all procedures are required. Six (6) subjects will be enrolled in the cohort in order to have 4 evaluable subjects.
The study will consist of a screening period (Day -21 to -2), a baseline period (Day -1), a single dose treatment on Day 1 with a minimum of 96 hours (=4 days) post dose in-house observation period (Days -1 up to afternoon Day 5), and a follow-up visit 30 days (±2 days) after the [14C]BTZ-043 dose.
Subjects will be administered a single 500 mg [14C]BTZ-043 dose as drinking suspension. Subjects will be confined to the clinical site for at least 96 hours following drug administration (ie, afternoon of Day 5). During this time, blood, feces, and urine samples for measurement of [14C]BTZ-043 and metabolites will be collected.
The subjects will be released from the clinic approximately 96 hours to 168 hours after dose administration and upon satisfactory recovery of radioactivity (at least 90%) approved by the Sponsor's scientific advisor after consulation of the Sponsor.
320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.
This study's enrollment of 4 is below the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.
Browse Tuberculosis, Pulmonary studies →Michael Hoelscher is the lead sponsor of 19 studies on the registry; 4 are open to participants now.
Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 subjects to receive a single oral administration of 14C-labeled radioactive 500mg BTZ-043
Drug: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043
Single oral administration of 14C-labeled radioactive 500mg BTZ-043
Rates and Routes of Excretion
To determine the rates and routes of excretion of \[14C\]BTZ-043-related radioactivity, including mass balance of total drug-related radioactivity in urine and feces (and vomit, if applicable), following the oral administration of a single 500 mg dose of \[14C\]BTZ-043 in healthy male volunteers. All excreta were collected for the analysis for 14C quick or normal counts of total radioactivity (as feasible). the radioactivity measured was translated into mg eq (Radioactivity equivalent to 1 mg BTZ-043).
Time frame: Urine and faeces were collected from the administration of the study medication until cumulative excretion reached 90% of total radioactivity administered. This was achieved by all subjects after 168 hours.
Pharmacokinetics of Total Radioactivity in Blood and Plasma (Cmax)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Pharmacokinetics of Total Radioactivity in Blood and Plasma (AUC-t)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Pharmacokinetics of Total Radioactivity in Blood (T1/2)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Pharmacokinetics of Total Radioactivity in Plasma (T1/2)
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
Time frame: Blood samples for total radioactivity were collected from day 1 until 168 h post dosing
Plasma PK of BTZ-043 and Main Metabolites (Cmax)
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites.Pharmacokinetic parameters are calculated from the individual plasma level measurements.
Time frame: Day 1 to Day 3
Plasma PK of BTZ-043 and Main Metabolites (AUC-last)
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.
Time frame: Day 1 to Day 3
Plasma PK of BTZ-043 and Main Metabolites (t1/2)
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.
Time frame: Day 1 to Day 3
Urine Concentrations of BTZ-043 and Main Metabolites
Urine volume was measured after every micturation and hamilton pools have been prepared for analysis of BTZ-043 and main metabolites by LC-MS. BTZ-043 could only be measured in urine within the first 24h, then no additional BTZ-043 was excreted in urine anymore. The same applies for M1. M2, M4 total and M10 total excretion could be measured in urine up to 48h post dose.
Time frame: Assessed from time of dosing up to 168 h post dose. BTZ-043 and metabolites were excreted fom 0 - 24 h (BTZ-043 and M1) and from 0 - 48 h (M2, M4 total and M10 total).
Number of Adverse Events
To assess the safety and tolerability of a single 500 mg oral dose of BTZ-043 administered to healthy volunteers.
Time frame: Day -1 to day 32
Screening started on 27th September 2021. The first participant was enrolled on October 8th, 2021. The healthy volunteers were recruited by PRA Health Sciences - Early Development Services in 9728 NZ Groningen
| Milestone | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Started | 4 |
| Completed | 4 |
| Not completed | 0 |
To determine the rates and routes of excretion of \[14C\]BTZ-043-related radioactivity, including mass balance of total drug-related radioactivity in urine and feces (and vomit, if applicable), following the oral administration of a single 500 mg dose of \[14C\]BTZ-043 in healthy male volunteers. All excreta were collected for the analysis for 14C quick or normal counts of total radioactivity (as feasible). the radioactivity measured was translated into mg eq (Radioactivity equivalent to 1 mg BTZ-043).
| mg eq | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| total drug-related radioactivity in urine | 331 ± 23.2 |
| total drug-related radioactivity in faeces | 162 ± 23.0 |
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
| ng eq/mL | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Cmax Plasma | 8730 ± 2550 |
| Cmax Blood | 4970 ± 1370 |
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
| h*ng eq/mL | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| AUC-t Plasma | 125000 ± 26900 |
| AUC-t Blood | 76700 ± 18500 |
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
| h | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Pharmacokinetics of Total Radioactivity in Blood (T1/2) | 158 ± 24.7 |
To determine the pharmacokinetics (PK) of total radioactivity in whole blood and in plasma. Measured radioactivity was translated into ng equivalent of BTZ-043. Based on the ng eq, pharmacokinetic parameters were calculated.
| h | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Pharmacokinetics of Total Radioactivity in Plasma (T1/2) | 186 ± 18.9 |
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites.Pharmacokinetic parameters are calculated from the individual plasma level measurements.
| ng/mL | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Cmax BTZ-043 | 1600 ± 509 |
| Cmax M1 | 163 ± 27.5 |
| Cmax M2 | 5180 ± 1310 |
| Cmax M4total | 1190 ± 455 |
| Cmax M10 | 30.6 ± 6.50 |
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.
| h*ng/mL | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| AUClast BTZ-043 | 3920 ± 842 |
| AUClast M1 | 2710 ± 433 |
| AUClast M2 | 41000 ± 6220 |
| AUClast M4total | 10300 ± 3990 |
| AUClast M10 | 505 ± 199 |
To characterize the plasma PK of BTZ-043 and main metabolites by liquid chromatography-mass spectrometry (LC-MS), if applicable. BTZ-043 is metabolized in the human body. Some of the metabolites were known prior to this study like the main metabolite M2, a hydrid Meisenheimer complex or the aminometabolite M1. Metabolite M4 and M10 were known before as well, therefore, the bioanalytical methods mentioned above could be developed and validated for these metabolites. Pharmacokinetic parameters are calculated from the individual plasma level measurements.
| h | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| T1/2 BTZ-043 | 2.43 ± 1.01 |
| T1/2 M1 | 8.65 ± 0 |
| T1/2 M2 | 4.90 ± 0.591 |
| T1/2 M4total | 3.83 ± 0.281 |
| T1/2 M10 | 18.9 ± 10.2 |
Urine volume was measured after every micturation and hamilton pools have been prepared for analysis of BTZ-043 and main metabolites by LC-MS. BTZ-043 could only be measured in urine within the first 24h, then no additional BTZ-043 was excreted in urine anymore. The same applies for M1. M2, M4 total and M10 total excretion could be measured in urine up to 48h post dose.
| mg eq | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| BTZ-043 (M0) Cumulative Amount Excreted 0 - 24h | 8.83 ± 4.51 |
| M1 Cumulative Amount Excreted 0 - 24h | 1.53 ± 0.518 |
| M2 Cumulative Amount Excreted 0 - 24h | 53.9 ± 17.1 |
| M2 Cumulative Amount Excreted 0 - 48h | 54.7 ± 17.3 |
| M4 total Cumulative Amount Excreted 0 - 24h | 59.4 ± 9.77 |
| M4 total Cumulative Amount Excreted 0 - 48h | 60.5 ± 10.2 |
| M10 total Cumulative Amount Excreted 0 - 24h | 2.47 ± 1.33 |
| M10 total Cumulative Amount Excreted 0 - 48h | 2.65 ± 1.45 |
| Sum(M0, M1, M2, M4total, M10) Cumulative Amount Excreted 0-24h | 126 ± 15.7 |
| Sum(M0, M1, M2, M4total, M10) Cumulative Amount Excreted 0-48h | 128 ± 16.4 |
To assess the safety and tolerability of a single 500 mg oral dose of BTZ-043 administered to healthy volunteers.
| Adverse Events | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Number of Adverse Events | 6 |
Collected over Day -1 (admission) until follow-up on day 31 or 32. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| DizzinessNervous system disorders | 4/4 |
| SomnolenceNervous system disorders | 1/4 |
| Oral HerpesInfections and infestations | 1/4 |
| Age, Categorical(Participants) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 0 |
| Age, Continuous(years) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Mean | 22 ± 3 |
| Sex/Gender, Customized(Participants) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Male | 4 |
| Race/Ethnicity, Customized(Participants) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Race — White | 3 |
| Race — White + Black or African American | 1 |
| Region of Enrollment(participants) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Netherlands | 4 |
| BMI(kg/m²) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Mean | 24.3 ± 4.0 |
| Height(cm) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Mean | 177 ± 2 |
| Weight(kg) | Single Oral Administration of 500 mg BTZ-043 Containing 3.7 MBq of [14C]BTZ-043 |
|---|---|
| Mean | 75.7 ± 13.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Oct 2021, 0 months.
Results were first posted in Dec 2024, 3 years 1 month after primary completion.
Of 13 phase 1 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 13. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Michael Hoelscher